FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225749775> ?p ?o ?g. }

• W4225749775 abstract "The risk/benefit tradeoff of dual antiplatelet therapy after percutaneous coronary intervention may vary in East Asian patients as compared with their non-East Asian counterparts.The double-blind, placebo-controlled, randomized TWILIGHT trial (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) enrolled patients undergoing high-risk percutaneous coronary intervention. After 3 months of treatment with ticagrelor plus aspirin, event-free and adherent patients remained on ticagrelor and were randomly assigned to receive aspirin or placebo for 1 year. The primary end point was Bleeding Academic Research Consortium type 2, 3, or 5 bleeding; the key secondary end point was the first occurrence of death from any cause, nonfatal myocardial infarction, or nonfatal stroke.Of 9006 enrolled and 7119 randomized patients in TWILIGHT, 1169 patients (13.0%) were enrolled at 27 Chinese sites in this prespecified substudy, of whom 1028 (14.4%) patients were randomized after 3 months. The incidence of the primary end point was 6.2% in the ticagrelor+aspirin group versus 3.5% in the ticagrelor+placebo group between randomization and 1 year (hazard ratio, 0.56 [95% CI, 0.31-0.99]; P=0.048). The key secondary end point occurred in 3.4% of patients in the ticagrelor+aspirin group versus 2.4% in the ticagrelor+placebo group (hazard ratio, 0.70 [95% CI, 0.33-1.46]; P=0.34). There was no interaction between the region of randomization (China versus the rest of the world) and randomized treatment assignment in terms of the primary or key secondary end points.Ticagrelor monotherapy significantly reduced clinically relevant bleeding without increasing ischemic events as compared with ticagrelor plus aspirin in Chinese patients undergoing high-risk percutaneous coronary intervention.URL: https://www.gov; Unique identifier: NCT02270242." @default.
• W4225749775 created "2022-05-05" @default.
• W4225749775 creator A5002666243 @default.
• W4225749775 creator A5003831287 @default.
• W4225749775 creator A5004107603 @default.
• W4225749775 creator A5004428427 @default.
• W4225749775 creator A5007026783 @default.
• W4225749775 creator A5008714150 @default.
• W4225749775 creator A5015669756 @default.
• W4225749775 creator A5016139987 @default.
• W4225749775 creator A5016812434 @default.
• W4225749775 creator A5016839056 @default.
• W4225749775 creator A5017670878 @default.
• W4225749775 creator A5020241086 @default.
• W4225749775 creator A5024220356 @default.
• W4225749775 creator A5027745740 @default.
• W4225749775 creator A5030931393 @default.
• W4225749775 creator A5032930728 @default.
• W4225749775 creator A5034764782 @default.
• W4225749775 creator A5034855917 @default.
• W4225749775 creator A5035818214 @default.
• W4225749775 creator A5036640081 @default.
• W4225749775 creator A5040356605 @default.
• W4225749775 creator A5040418600 @default.
• W4225749775 creator A5041882455 @default.
• W4225749775 creator A5045787776 @default.
• W4225749775 creator A5050215601 @default.
• W4225749775 creator A5051858597 @default.
• W4225749775 creator A5056506041 @default.
• W4225749775 creator A5057167171 @default.
• W4225749775 creator A5057974711 @default.
• W4225749775 creator A5059127209 @default.
• W4225749775 creator A5064842058 @default.
• W4225749775 creator A5066606190 @default.
• W4225749775 creator A5079324557 @default.
• W4225749775 creator A5083495465 @default.
• W4225749775 creator A5087034276 @default.
• W4225749775 creator A5087944559 @default.
• W4225749775 creator A5089035999 @default.
• W4225749775 creator A5091605767 @default.
• W4225749775 date "2022-04-01" @default.
• W4225749775 modified "2023-10-11" @default.
• W4225749775 title "Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy" @default.
• W4225749775 cites W2040823835 @default.
• W4225749775 cites W2087150869 @default.
• W4225749775 cites W2102398982 @default.
• W4225749775 cites W2337269527 @default.
• W4225749775 cites W2474556142 @default.
• W4225749775 cites W2526267487 @default.
• W4225749775 cites W2567143898 @default.
• W4225749775 cites W2607096599 @default.
• W4225749775 cites W2761824840 @default.
• W4225749775 cites W2809722890 @default.
• W4225749775 cites W2907776863 @default.
• W4225749775 cites W2916912835 @default.
• W4225749775 cites W2920948042 @default.
• W4225749775 cites W2954135047 @default.
• W4225749775 cites W2973850987 @default.
• W4225749775 cites W2976166882 @default.
• W4225749775 cites W3005964164 @default.
• W4225749775 cites W3007567019 @default.
• W4225749775 cites W4211143229 @default.
• W4225749775 cites W4292856638 @default.
• W4225749775 doi "https://doi.org/10.1161/circinterventions.120.009495" @default.
• W4225749775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35317615" @default.
• W4225749775 hasPublicationYear "2022" @default.
• W4225749775 type Work @default.
• W4225749775 citedByCount "2" @default.
• W4225749775 countsByYear W42257497752022 @default.
• W4225749775 crossrefType "journal-article" @default.
• W4225749775 hasAuthorship W4225749775A5002666243 @default.
• W4225749775 hasAuthorship W4225749775A5003831287 @default.
• W4225749775 hasAuthorship W4225749775A5004107603 @default.
• W4225749775 hasAuthorship W4225749775A5004428427 @default.
• W4225749775 hasAuthorship W4225749775A5007026783 @default.
• W4225749775 hasAuthorship W4225749775A5008714150 @default.
• W4225749775 hasAuthorship W4225749775A5015669756 @default.
• W4225749775 hasAuthorship W4225749775A5016139987 @default.
• W4225749775 hasAuthorship W4225749775A5016812434 @default.
• W4225749775 hasAuthorship W4225749775A5016839056 @default.
• W4225749775 hasAuthorship W4225749775A5017670878 @default.
• W4225749775 hasAuthorship W4225749775A5020241086 @default.
• W4225749775 hasAuthorship W4225749775A5024220356 @default.
• W4225749775 hasAuthorship W4225749775A5027745740 @default.
• W4225749775 hasAuthorship W4225749775A5030931393 @default.
• W4225749775 hasAuthorship W4225749775A5032930728 @default.
• W4225749775 hasAuthorship W4225749775A5034764782 @default.
• W4225749775 hasAuthorship W4225749775A5034855917 @default.
• W4225749775 hasAuthorship W4225749775A5035818214 @default.
• W4225749775 hasAuthorship W4225749775A5036640081 @default.
• W4225749775 hasAuthorship W4225749775A5040356605 @default.
• W4225749775 hasAuthorship W4225749775A5040418600 @default.
• W4225749775 hasAuthorship W4225749775A5041882455 @default.
• W4225749775 hasAuthorship W4225749775A5045787776 @default.
• W4225749775 hasAuthorship W4225749775A5050215601 @default.
• W4225749775 hasAuthorship W4225749775A5051858597 @default.
• W4225749775 hasAuthorship W4225749775A5056506041 @default.
• W4225749775 hasAuthorship W4225749775A5057167171 @default.
• W4225749775 hasAuthorship W4225749775A5057974711 @default.
• W4225749775 hasAuthorship W4225749775A5059127209 @default.

• next